EXAS240920C65000
- 5.18
- -1.34-20.55%
Exact Sciences Newsroom
Jefferies Maintains Exact Sciences(EXAS.US) With Buy Rating, Maintains Target Price $84
A Quick Look at Today's Ratings for Exact Sciences(EXAS.US), With a Forecast Between $75 to $84
Buy Rating Affirmed for Exact Sciences on Robust CRC Test Results and Strategic Pipeline Advancements
Canaccord Genuity Maintains Buy on Exact Sciences, Maintains $75 Price Target
CCORF Maintains Exact Sciences(EXAS.US) With Buy Rating, Maintains Target Price $75
Analysts Offer Insights on Healthcare Companies: Seres Therapeutics (MCRB), BioMarin Pharmaceutical (BMRN) and Exact Sciences (EXAS)
Piper Sandler Maintains Exact Sciences(EXAS.US) With Buy Rating, Raises Target Price to $85
Exact Sciences Is Maintained at Overweight by Piper Sandler
Exact Sciences Analyst Ratings
Evercore Maintains Exact Sciences(EXAS.US) With Buy Rating, Maintains Target Price $72
Buy Rating for Exact Sciences: Anticipated Growth From Upcoming Catalysts and Competitive Pricing
Buy Rating Affirmed for Exact Sciences Amid Promising Cancer Screening Innovations and Strategic Advantages
Jefferies Maintains Exact Sciences(EXAS.US) With Buy Rating, Maintains Target Price $84
Jefferies Maintains Exact Sciences(EXAS.US) With Buy Rating, Maintains Target Price $75
Exact Sciences Price Target Announced at $75.00/Share by Wells Fargo
Exact Sciences Initiated at Overweight by Wells Fargo
Exact Sciences Analyst Ratings
Wells Fargo Initiates Coverage On Exact Sciences With Overweight Rating, Announces Price Target of $75
Analysts Offer Insights on Healthcare Companies: Alignment Healthcare (ALHC), Exact Sciences (EXAS) and Fulcrum Therapeutics (FULC)
Scotiabank Maintains Exact Sciences(EXAS.US) With Buy Rating, Maintains Target Price $70